×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical_Trial: Pain in Parkinson's Disease: Exploration of the Serotonin Sy
clinical_trial
1,064 words
KG: pain
2026-03-31
clinical-trial
parkinson
biomarker
neuroimaging
serotonin
pet
pain
Contents
Pain in Parkinson's Disease: Exploration of the Serotonin System in PET
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.62
Senescence-Activated NAD+ Depletion Rescue
Score: 0.60
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.59
Microbial Inflammasome Priming Prevention
Score: 0.58
PARP1 Inhibition Therapy
Score: 0.58
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
Adenosine-Astrocyte Metabolic Reset
Score: 0.56
Blood-Brain Barrier SPM Shuttle System
Score: 0.55
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Epigenetic Memory Erasure via TET2 Activation
Score: 0.52
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.51
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A
Score: 0.51
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50
Orexin-Microglia Modulation Therapy
Score: 0.49
Microglial Purinergic Reprogramming
Score: 0.48
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48
Show 25 more
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Show 25 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
See Also (7)
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: associated_with
Packard Center for ALS Research
institution · KG edge: activates
Alzheimer Indonesia
institution · KG edge: activates
PIEZO2 — Piezo Type Mechanosensitive Ion Channel Compon
gene · KG edge: regulates
Amyloid-Related Imaging Abnormalities (ARIA)
entity · KG edge: therapeutic_target
AMPK (AMP-Activated Protein Kinase)
entity · KG edge: activates
Amyotrophic Lateral Sclerosis
redirect · KG edge: activates
Show 2 more
Knowledge Graph (1 edges)
PIEZO2
regulates
pain